is a type of poisoning or infection caused by certain bacteria on the preserved food material. It is a rare but very serious illness which disseminates through food coming in contact with contaminated soil or an open wound. It produces a toxin that affects the nervous system whose early diagnosis is crucial for the survival. Delay in the treatment can result in paralysis, respiratory failure or even death as movement of muscles and respiration becomes difficult for the person affected with botulism. Constipation, drooping eyelids, blurred vision, nausea, dry mouth and so on are some of the major symptoms of botulism. Advancements in medical science have brought various types of drugs for the treatment of botulism. Increased efforts in research & development and availability of effective solutions are the key drivers that fuel the market growth of botulism during the forecast period 2016-2021.
report is segment by type and by drug type. By type, botulism market is categorized into infant botulism and adult botulism which is further classifies into foodborne botulism and wound botulism. Among these, infant botulism cases are the highest across the globe with around two third of the total botulism cases. Such diseases can be treated by antibiotics and anti-toxin such as HBA and Trivalen.
The overall botulism market also provides a detailed analysis of the type and treatment in various regions which includes Americas, Europe, Asia Pacific and Rest of the World. Americas lead the botulism market owing to the largest number of botulism cases every year. APAC region tends to become highly promising in near future. Global botulism treatment market is estimated to reach $XXm in 2021 from $XXm in 2015 growing at a CAGR of XX during 2016-2021.
Along with the in-depth market segmentation, the report has also analyzed competitive landscape, strategies of key players, major company profiles and changing market dynamics of the industry.
Key players of the market include:
- XOMA Corporation (U.S.)
- Alphavax Inc. (U.S.)
- Microbiotix Inc. (U.S.)
- Morphotek Inc. (U.S.)
- Valeant Pharmaceuticals Inc. (Canada).